Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

Hisato Kawakami, Isamu Okamoto, Hidetoshi Hayashi, Masataka Taguri, Satoshi Morita, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background With the increasing availability of active agents, the importance of postprogression survival (PPS) has been recognised for several malignancies. However, little is known of PPS in advanced gastric cancer. Patients and methods A literature search identified 43 randomised trials in chemotherapy-naive patients with advanced gastric cancer. We partitioned overall survival (OS) into progression-free survival (PFS) and PPS, and then examined the correlation between median OS and either median PFS or median PPS. The correlation between differences in OS (ΔOS) and those in PFS (ΔPFS) between trial arms was also investigated. Results The average median OS was significantly longer in recent (2006 and later) trials than in older (2005 and earlier) trials (10.60 versus 8.64 months, P < 0.001), as was the average median PPS (5.34 versus 3.74 months, P = 0.001). Median PPS was correlated with median OS for all trials (r = 0.732), and this correlation was more pronounced in recent trials (r = 0.850). By contrast, the correlation between median PFS and median OS was less pronounced in recent trials (r = 0.282), as was that between ΔPFS and ΔOS (r = 0.365). Conclusion An increase in median PPS was found in accordance with an increase in median OS in recent trials compared with older trials for patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)3003-3009
Number of pages7
JournalEuropean Journal of Cancer
Volume49
Issue number14
DOIs
Publication statusPublished - Sep 1 2013

Fingerprint

Stomach Neoplasms
Drug Therapy
Survival
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. / Kawakami, Hisato; Okamoto, Isamu; Hayashi, Hidetoshi; Taguri, Masataka; Morita, Satoshi; Nakagawa, Kazuhiko.

In: European Journal of Cancer, Vol. 49, No. 14, 01.09.2013, p. 3003-3009.

Research output: Contribution to journalArticle

Kawakami, Hisato ; Okamoto, Isamu ; Hayashi, Hidetoshi ; Taguri, Masataka ; Morita, Satoshi ; Nakagawa, Kazuhiko. / Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. In: European Journal of Cancer. 2013 ; Vol. 49, No. 14. pp. 3003-3009.
@article{2d2986debdb149b48ff0632780e21134,
title = "Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer",
abstract = "Background With the increasing availability of active agents, the importance of postprogression survival (PPS) has been recognised for several malignancies. However, little is known of PPS in advanced gastric cancer. Patients and methods A literature search identified 43 randomised trials in chemotherapy-naive patients with advanced gastric cancer. We partitioned overall survival (OS) into progression-free survival (PFS) and PPS, and then examined the correlation between median OS and either median PFS or median PPS. The correlation between differences in OS (ΔOS) and those in PFS (ΔPFS) between trial arms was also investigated. Results The average median OS was significantly longer in recent (2006 and later) trials than in older (2005 and earlier) trials (10.60 versus 8.64 months, P < 0.001), as was the average median PPS (5.34 versus 3.74 months, P = 0.001). Median PPS was correlated with median OS for all trials (r = 0.732), and this correlation was more pronounced in recent trials (r = 0.850). By contrast, the correlation between median PFS and median OS was less pronounced in recent trials (r = 0.282), as was that between ΔPFS and ΔOS (r = 0.365). Conclusion An increase in median PPS was found in accordance with an increase in median OS in recent trials compared with older trials for patients with advanced gastric cancer.",
author = "Hisato Kawakami and Isamu Okamoto and Hidetoshi Hayashi and Masataka Taguri and Satoshi Morita and Kazuhiko Nakagawa",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.ejca.2013.05.022",
language = "English",
volume = "49",
pages = "3003--3009",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

AU - Kawakami, Hisato

AU - Okamoto, Isamu

AU - Hayashi, Hidetoshi

AU - Taguri, Masataka

AU - Morita, Satoshi

AU - Nakagawa, Kazuhiko

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background With the increasing availability of active agents, the importance of postprogression survival (PPS) has been recognised for several malignancies. However, little is known of PPS in advanced gastric cancer. Patients and methods A literature search identified 43 randomised trials in chemotherapy-naive patients with advanced gastric cancer. We partitioned overall survival (OS) into progression-free survival (PFS) and PPS, and then examined the correlation between median OS and either median PFS or median PPS. The correlation between differences in OS (ΔOS) and those in PFS (ΔPFS) between trial arms was also investigated. Results The average median OS was significantly longer in recent (2006 and later) trials than in older (2005 and earlier) trials (10.60 versus 8.64 months, P < 0.001), as was the average median PPS (5.34 versus 3.74 months, P = 0.001). Median PPS was correlated with median OS for all trials (r = 0.732), and this correlation was more pronounced in recent trials (r = 0.850). By contrast, the correlation between median PFS and median OS was less pronounced in recent trials (r = 0.282), as was that between ΔPFS and ΔOS (r = 0.365). Conclusion An increase in median PPS was found in accordance with an increase in median OS in recent trials compared with older trials for patients with advanced gastric cancer.

AB - Background With the increasing availability of active agents, the importance of postprogression survival (PPS) has been recognised for several malignancies. However, little is known of PPS in advanced gastric cancer. Patients and methods A literature search identified 43 randomised trials in chemotherapy-naive patients with advanced gastric cancer. We partitioned overall survival (OS) into progression-free survival (PFS) and PPS, and then examined the correlation between median OS and either median PFS or median PPS. The correlation between differences in OS (ΔOS) and those in PFS (ΔPFS) between trial arms was also investigated. Results The average median OS was significantly longer in recent (2006 and later) trials than in older (2005 and earlier) trials (10.60 versus 8.64 months, P < 0.001), as was the average median PPS (5.34 versus 3.74 months, P = 0.001). Median PPS was correlated with median OS for all trials (r = 0.732), and this correlation was more pronounced in recent trials (r = 0.850). By contrast, the correlation between median PFS and median OS was less pronounced in recent trials (r = 0.282), as was that between ΔPFS and ΔOS (r = 0.365). Conclusion An increase in median PPS was found in accordance with an increase in median OS in recent trials compared with older trials for patients with advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84883053473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883053473&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.05.022

DO - 10.1016/j.ejca.2013.05.022

M3 - Article

C2 - 23791540

AN - SCOPUS:84883053473

VL - 49

SP - 3003

EP - 3009

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0959-8049

IS - 14

ER -